{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:01:05Z","timestamp":1780981265031,"version":"3.54.1"},"reference-count":143,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Sodium-glucose cotransporter 2 (SGLT2) inhibitors were originally developed as glucose-lowering agents for type 2 diabetes mellitus, but accumulating evidence has demonstrated their broad cardiovascular and cardiorenal benefits beyond glycemic control. In particular, empagliflozin and dapagliflozin have shown robust prognostic benefits in heart failure with reduced ejection fraction (HFrEF) and expanding therapeutic value in heart failure with preserved ejection fraction (HFpEF). However, their cardiovascular protection cannot be fully explained by glucose lowering alone and is likely mediated through a multilayered network of systemic, metabolic, vascular, and cellular mechanisms. This integrative narrative review summarizes current mechanistic and clinical evidence regarding SGLT2 inhibitors in cardiovascular disease and proposes a translational framework linking hemodynamic rebalancing, cardiometabolic reprogramming, vascular protection, redox homeostasis, mitochondrial quality control, immunometabolic modulation, and attenuation of adverse myocardial remodeling. Clinically, the strongest evidence has been established in heart failure, whereas data in ischemic heart disease, post-myocardial infarction remodeling, and arrhythmias remain promising but less definitive. In post-myocardial infarction settings, SGLT2 inhibitors may improve N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, ventricular remodeling parameters, and heart failure-related outcomes, although effects on hard clinical endpoints remain inconsistent. For atrial arrhythmias, emerging evidence suggests a potential reduction in atrial fibrillation or flutter risk, but dedicated trials are still required. Safety considerations, including genital infections, volume depletion, renal function changes, euglycemic ketoacidosis, and perioperative management, should also be incorporated into individualized clinical decision-making. Overall, SGLT2 inhibitors should be viewed as cardiovascular-metabolic modulators acting through interconnected mechanisms, with future research needed to clarify phenotype-specific benefits and optimize their precision use in cardiovascular disease.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1776906","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:34:15Z","timestamp":1780979655000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations"],"prefix":"10.3389","volume":"13","author":[{"given":"Ziyun","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, The Affiliated Hospital, Southwest Medical University","place":["Luzhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, The Affiliated Hospital, Southwest Medical University","place":["Luzhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangning","family":"Shangguan","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children\u2019s Hospital of Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, The Affiliated Hospital, Southwest Medical University","place":["Luzhou, Sichuan, China"]},{"name":"Department of Anesthesiology, Laboratory of Mitochondria and Metabolism, National-Local Joint Engineering Research Centre of Translational Medicine of Anesthesiology, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.jacc.2025.08.015","article-title":"Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990\u20132023","volume":"86","author":"Stark","year":"2025","journal-title":"JACC"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global burden of cardiovascular diseases and risks, 1990\u20132022","volume":"82","author":"Mensah","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/eurjpc\/zwae281","article-title":"Global burden of cardiovascular diseases: projections from 2025 to 2050","volume":"32","author":"Chong","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5334\/gh.1288","article-title":"The heart of the world","volume":"19","author":"Di Cesare","year":"2024","journal-title":"Glob Heart"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e038644","DOI":"10.1161\/JAHA.124.038644","article-title":"Heart disease mortality in the United States, 1970 to 2022","volume":"14","author":"King","year":"2025","journal-title":"JAHA"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacasi.2025.08.024","article-title":"Burden and risk factors of cardiovascular diseases in Asia, 1990\u20132021: an analysis for GBD 2021","author":"Zhang","year":"2025","journal-title":"JACC Asia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1038\/sj.ki.5002383","article-title":"Regulatory mechanisms of na +\/glucose cotransporters in renal proximal tubule cells","volume":"72","author":"Lee","year":"2007","journal-title":"Kidney Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","article-title":"Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications","volume":"27","author":"Gerich","year":"2010","journal-title":"Diabetic Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1038\/ki.2010.512","article-title":"Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans","volume":"79","author":"List","year":"2011","journal-title":"Kidney Int"},{"key":"B11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 Inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40262-015-0264-4","article-title":"Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes Mellitus and chronic kidney disease","volume":"54","author":"Scheen","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium\u2013glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes Mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes Mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s13300-014-0089-4","article-title":"Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology","volume":"5","author":"Kalra","year":"2014","journal-title":"Diabetes Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/ajh\/hpae092","article-title":"State-of-the-Art-Review: mechanisms of action of SGLT2 inhibitors and clinical implications","volume":"37","author":"Vallon","year":"2024","journal-title":"Am J Hypertens"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.34067\/KID.0002772021","article-title":"SGLT2 Inhibitors: physiology and pharmacology","volume":"2","author":"Wright","year":"2021","journal-title":"Kidney360"},{"key":"B19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diab Obes Metab"},{"key":"B20","doi-asserted-by":"publisher","first-page":"777861","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-Glucose cotransporter 2 inhibitors mechanisms of action: a review","volume":"8","author":"Fonseca-Correa","year":"2021","journal-title":"Front Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.eprac.2024.03.001","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on the 24-hour ambulatory blood pressure in patients with type 2 diabetes Mellitus and hypertension: an updated meta-analysis","volume":"30","author":"Iqbal","year":"2024","journal-title":"Endocr Pract"},{"key":"B22","doi-asserted-by":"publisher","first-page":"102304","DOI":"10.1016\/j.jacadv.2025.102304","article-title":"Effect of empagliflozin on whole body, cardiac, and renal sympathetic outflows in type 2 diabetes","volume":"4","author":"Reutens","year":"2025","journal-title":"JACC: Advances"},{"key":"B23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s11892-012-0275-6","article-title":"Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes Mellitus","volume":"12","author":"Abdul-Ghani","year":"2012","journal-title":"Curr Diab Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"F361","DOI":"10.1152\/ajprenal.00070.2022","article-title":"SGLT2 Inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats","volume":"323","author":"Masuda","year":"2022","journal-title":"Am J Physiol Renal Physiology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0279889","DOI":"10.1371\/journal.pone.0279889","article-title":"Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"17","author":"Pan","year":"2022","journal-title":"PLoS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes Mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12933-024-02539-x","article-title":"SGLT2 Inhibition and adipose tissue metabolism: current outlook and perspectives","volume":"23","author":"Morciano","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/dom.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"Bailey","year":"2019","journal-title":"Diab Obes Metabolism"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e003836","DOI":"10.1136\/bmjdrc-2023-003836","article-title":"Effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on serum uric acid levels in patients with chronic kidney disease: a systematic review and network meta-analysis","volume":"12","author":"Zhang","year":"2024","journal-title":"BMJ Open Diab Res Care"},{"key":"B30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s13098-023-01182-y","article-title":"Effects of empagliflozin on serum uric acid level of patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"15","author":"You","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"B31","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41440-024-02031-9","article-title":"Current updates and future perspectives in uric acid research, 2024","volume":"48","author":"Kuwabara","year":"2025","journal-title":"Hypertens Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","article-title":"Hyperuricemia and its related diseases: mechanisms and advances in therapy","volume":"9","author":"Du","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1093\/eurheartj\/ehad484","article-title":"Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers","volume":"44","author":"Antoniades","year":"2023","journal-title":"Eur Heart J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s12933-023-02091-0","article-title":"Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes","volume":"22","author":"Cinti","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/j.jacc.2021.02.057","article-title":"Therapeutic manipulation of myocardial metabolism","volume":"77","author":"Honka","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1056\/NEJMra063052","article-title":"The failing heart \u2014 an engine out of fuel","volume":"356","author":"Neubauer","year":"2007","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac energy metabolism in heart failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circ Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1093\/cvr\/cvae231","article-title":"Advances in myocardial energy metabolism: metabolic remodelling in heart failure and beyond","volume":"120","author":"Sun","year":"2024","journal-title":"Cardiovasc Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"H1060","DOI":"10.1152\/ajpheart.00646.2012","article-title":"Ketone body metabolism and cardiovascular disease","volume":"304","author":"Cotter","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12997\/jla.2022.11.1.1","article-title":"SGLT2 Inhibitors and ketone metabolism in heart failure","volume":"11","author":"Saucedo-Orozco","year":"2022","journal-title":"J Lipid Atheroscler"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1161\/CIRCULATIONAHA.122.062021","article-title":"Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: the randomized, controlled EMPA-VISION trial","volume":"147","author":"Hundertmark","year":"2023","journal-title":"Circulation"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e651","DOI":"10.1002\/mco2.651","article-title":"Endothelial dysfunction: molecular mechanisms and clinical implications","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"key":"B44","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3390\/biom14050592","article-title":"Dapagliflozin improves angiogenesis after hindlimb ischemia through the PI3K-akt-eNOS pathway","volume":"14","author":"Han","year":"2024","journal-title":"Biomolecules"},{"key":"B45","doi-asserted-by":"publisher","first-page":"116994","DOI":"10.1016\/j.biopha.2024.116994","article-title":"SGLT2 Inhibitor dapagliflozin alleviates cardiac dysfunction and fibrosis after myocardial infarction by activating PXR and promoting angiogenesis","volume":"177","author":"Wang","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3389\/fphys.2019.01173","article-title":"The role of Sirtuin1 in regulating endothelial function, arterial remodeling and vascular aging","volume":"10","author":"Man","year":"2019","journal-title":"Front Physiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"484","DOI":"10.7150\/ijbs.78654","article-title":"Novel role of the SIRT1 in endocrine and metabolic diseases","volume":"19","author":"Lu","year":"2023","journal-title":"Int J Biol Sci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1093\/cvr\/cvad102","article-title":"Chronic SIRT1 supplementation in diabetic mice improves endothelial function by suppressing oxidative stress","volume":"119","author":"Yang","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"115213","DOI":"10.1016\/j.biopha.2023.115213","article-title":"Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation","volume":"165","author":"Zhou","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e19152","DOI":"10.1016\/j.heliyon.2023.e19152","article-title":"Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes","volume":"9","author":"Tai","year":"2023","journal-title":"Heliyon"},{"key":"B51","doi-asserted-by":"publisher","first-page":"865","DOI":"10.33594\/000000178","article-title":"Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor \u03b1-stimulated human coronary arterial endothelial cells","volume":"53","author":"Uthman","year":"2019","journal-title":"Cell Physiol Biochem"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e035044","DOI":"10.1161\/JAHA.124.035044","article-title":"Empagliflozin attenuates neointima formation after arterial injury and inhibits smooth muscle cell proliferation and migration by suppressing platelet-derived growth factor\u2013related signaling","volume":"13","author":"Chang","year":"2024","journal-title":"JAHA"},{"key":"B53","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41401-023-01217-0","article-title":"Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation","volume":"45","author":"Li","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"B54","doi-asserted-by":"publisher","first-page":"10490","DOI":"10.1039\/D4TB01126K","article-title":"Alleviating hypoxia and oxidative stress for treatment of cardiovascular diseases: a biomaterials perspective","volume":"12","author":"Athmuri","year":"2024","journal-title":"J Mater Chem B"},{"key":"B55","doi-asserted-by":"publisher","first-page":"165768","DOI":"10.1016\/j.bbadis.2020.165768","article-title":"Mitochondrial ROS in myocardial ischemia reperfusion and remodeling","volume":"1866","author":"Bugger","year":"2020","journal-title":"Biochimica et Biophysica Acta (BBA) - Mol Basis Dis"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1007\/s40279-018-0996-z","article-title":"Oxidative stress and inflammation, key targets of atherosclerotic plaque progression and vulnerability: potential impact of physical activity","volume":"48","author":"Mury","year":"2018","journal-title":"Sports Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"119573","DOI":"10.1016\/j.bbamcr.2023.119573","article-title":"Reactive oxygen species and cell signaling. Review","volume":"1871","author":"Averill-Bates","year":"2024","journal-title":"Biochimica et Biophysica Acta (BBA) - Mol Cell Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3390\/antiox13030312","article-title":"Reactive oxygen Species signaling and oxidative stress: transcriptional regulation and evolution","volume":"13","author":"Hong","year":"2024","journal-title":"Antioxidants"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.3390\/nu11092090","article-title":"Oxidative stress in cardiovascular diseases: still a therapeutic target?","volume":"11","author":"Senoner","year":"2019","journal-title":"Nutrients"},{"key":"B60","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-024-02095-6","article-title":"Redox regulation: mechanisms, biology and therapeutic targets in diseases","volume":"10","author":"Li","year":"2025","journal-title":"Sig Transduct Target Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e70268","DOI":"10.1002\/mco2.70268","article-title":"Oxidative stress: signaling pathways, biological functions, and disease","volume":"6","author":"Liu","year":"2025","journal-title":"MedComm"},{"key":"B62","doi-asserted-by":"publisher","first-page":"102979","DOI":"10.1016\/j.redox.2023.102979","article-title":"Empagliflozin prevents oxidative stress in human coronary artery endothelial cells via the NHE\/PKC\/NOX axis","volume":"69","author":"Li","year":"2024","journal-title":"Redox Biol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"177147","DOI":"10.1016\/j.ejphar.2024.177147","article-title":"Empagliflozin prevents TNF-\u03b1 induced endothelial dysfunction under flow -the potential involvement of calcium and sodium-hydrogen exchanger","volume":"986","author":"Li","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"176875","DOI":"10.1016\/j.ejphar.2024.176875","article-title":"Dapagliflozin alleviates right heart failure by promoting collagen degradation by reducing ROS levels","volume":"981","author":"Liu","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s12012-024-09945-3","article-title":"Dapagliflozin suppresses high glucose-induced proliferation, oxidative stress, and fibrosis by reducing Mettl3-induced m6A modification in marcks mRNA","volume":"25","author":"Shi","year":"2025","journal-title":"Cardiovasc Toxicol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"30764","DOI":"10.1038\/s41598-024-80829-w","article-title":"Effects of empagliflozin and dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction","volume":"14","author":"Ma","year":"2024","journal-title":"Sci Rep"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e29160","DOI":"10.1016\/j.heliyon.2024.e29160","article-title":"Dapagliflozin ameliorates myocardial infarction injury through AMPK\u03b1-dependent regulation of oxidative stress and apoptosis","volume":"10","author":"Peng","year":"2024","journal-title":"Heliyon"},{"key":"B68","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3390\/antiox13070831","article-title":"Canagliflozin inhibits palmitic acid-induced vascular cell aging in vitro through ROS\/ERK and ferroptosis pathways","volume":"13","author":"Wan","year":"2024","journal-title":"Antioxidants"},{"key":"B69","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/med.21732","article-title":"Mitochondrial dysfunction in cardiovascular disease: current status of translational research\/clinical and therapeutic implications","volume":"41","author":"Manolis","year":"2021","journal-title":"Med Res Rev"},{"key":"B70","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41569-022-00703-y","article-title":"The role of mitochondrial fission in cardiovascular health and disease","volume":"19","author":"Quiles","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.molmed.2022.06.007","article-title":"Mitophagy in cardiovascular diseases: molecular mechanisms, pathogenesis, and treatment","volume":"28","author":"Ajoolabady","year":"2022","journal-title":"Trends Mol Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0355-7","article-title":"Mitochondrial dysfunction and oxidative stress in heart disease","volume":"51","author":"Peoples","year":"2019","journal-title":"Exp Mol Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"120834","DOI":"10.1016\/j.lfs.2022.120834","article-title":"Assessment of mitochondrial dysfunction and implications in cardiovascular disorders","volume":"306","author":"Li","year":"2022","journal-title":"Life Sci"},{"key":"B74","doi-asserted-by":"publisher","first-page":"8235","DOI":"10.3390\/ijms25158235","article-title":"Empagliflozin prevent high-glucose stimulation inducing apoptosis and mitochondria fragmentation in H9C2 cells through the calcium-dependent activation extracellular signal-regulated kinase 1\/2 pathway","volume":"25","author":"Chen","year":"2024","journal-title":"IJMS"},{"key":"B75","doi-asserted-by":"publisher","first-page":"112320","DOI":"10.1016\/j.mce.2024.112320","article-title":"SGLT2 Inhibitor canagliflozin reduces visceral adipose tissue in db\/db mice by modulating AMPK\/KLF4 signaling and regulating mitochondrial dynamics to induce browning","volume":"592","author":"Qu","year":"2024","journal-title":"Mol Cell Endocrinol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/FJC.0000000000001625","article-title":"Canagliflozin mediates mitophagy through the AMPK\/PINK1\/parkin pathway to alleviate ISO-induced cardiac remodeling","volume":"84","author":"Gong","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"7008","DOI":"10.3390\/ijms25137008","article-title":"Canagliflozin mitigates diabetic cardiomyopathy through enhanced PINK1-parkin mitophagy","volume":"25","author":"Yang","year":"2024","journal-title":"IJMS"},{"key":"B78","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","article-title":"Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"e011107","DOI":"10.1161\/CIRCHEARTFAILURE.123.011107","article-title":"Empagliflozin improves diastolic function in HFpEF by restabilizing the mitochondrial respiratory chain","volume":"17","author":"Schauer","year":"2024","journal-title":"Circ: Heart Failure"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-Inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"II2","DOI":"10.1161\/01.CIR.0000129535.04194.38","article-title":"Inflammation as a cardiovascular risk factor","volume":"109","author":"Willerson","year":"2004","journal-title":"Circulation"},{"key":"B83","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1093\/eurheartj\/ehz645","article-title":"Inflammation, cardiovascular disease, and cancer: a common link with far-reaching implications","volume":"40","author":"Lancellotti","year":"2019","journal-title":"Eur Heart J"},{"key":"B84","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12933-024-02481-y","article-title":"Dapagliflozin mitigates cellular stress and inflammation through PI3\u2005K\/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived \u03b2 cells","volume":"23","author":"Alsereidi","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"122354","DOI":"10.1016\/j.lfs.2023.122354","article-title":"Empagliflozin protects against isoprenaline-induced fibrosis in rat heart through modulation of TGF-\u03b2\/SMAD pathway","volume":"337","author":"Elsayed","year":"2024","journal-title":"Life Sci"},{"key":"B86","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41392-024-01840-1","article-title":"Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets","volume":"9","author":"Chen","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"B87","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.molimm.2024.02.006","article-title":"Empagliflozin attenuates inflammation levels in autoimmune myocarditis through the STAT3 pathway and macrophage phenotype transformation","volume":"167","author":"Sheng","year":"2024","journal-title":"Mol Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"101334","DOI":"10.1016\/j.xcrm.2023.101334","article-title":"Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep. Med."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1042\/CS20171167","article-title":"Mechanisms contributing to cardiac remodelling","volume":"131","author":"Wu","year":"2017","journal-title":"Clin Sci"},{"key":"B90","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ejhf.2493","article-title":"Cardiac remodelling \u2013 part 1: from cells and tissues to circulating biomarkers. A review from the study group on biomarkers of the heart failure association of the European Society of Cardiology","volume":"24","author":"Gonz\u00e1lez","year":"2022","journal-title":"European J of Heart Fail"},{"key":"B91","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.7150\/ijbs.47180","article-title":"The roles of noncardiomyocytes in cardiac remodeling","volume":"16","author":"Yang","year":"2020","journal-title":"Int J Biol Sci"},{"key":"B92","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s12933-024-02477-8","article-title":"ALDH2 Mediates the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on improving cardiac remodeling","volume":"23","author":"Liu","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"116477","DOI":"10.1016\/j.biopha.2024.116477","article-title":"Empagliflozin mitigates cardiac hypertrophy through cardiac RSK\/NHE-1 inhibition","volume":"174","author":"Chen","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1499542","DOI":"10.3389\/fphar.2024.1499542","article-title":"Empagliflozin improves pressure-overload-induced cardiac hypertrophy by inhibiting the canonical wnt\/\u03b2-catenin signaling pathway","volume":"15","author":"Yuan","year":"2024","journal-title":"Front Pharmacol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1038\/s41401-022-00885-8","article-title":"Direct cardio-protection of dapagliflozin against obesity-related cardiomyopathy via NHE1\/MAPK signaling","volume":"43","author":"Lin","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"B96","doi-asserted-by":"publisher","first-page":"263","DOI":"10.21037\/cdt-20-302","article-title":"Pathophysiology of heart failure","volume":"11","author":"Schwinger","year":"2021","journal-title":"Cardiovasc Diagn Ther"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/ejhf.2707","article-title":"Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-reduced","volume":"24","author":"Filippatos","year":"2022","journal-title":"European J of Heart Fail"},{"key":"B99","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jchf.2023.06.036","article-title":"Efficacy and safety of empagliflozin according to background diuretic use in HFrEF","volume":"12","author":"Dhingra","year":"2024","journal-title":"JACC Heart Fail"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.jacc.2021.07.046","article-title":"Prognostic importance of NT-proBNP and effect of empagliflozin in the EMPEROR-reduced trial","volume":"78","author":"Januzzi","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1093\/eurheartj\/ehac320","article-title":"Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial","volume":"43","author":"Doehner","year":"2022","journal-title":"Eur Heart J"},{"key":"B102","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/ejhf.2409","article-title":"Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR- reduced","volume":"24","author":"Ferreira","year":"2022","journal-title":"European J of Heart Fail"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/eurheartj\/ehaa1007","article-title":"Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-reduced trial","volume":"42","author":"Butler","year":"2021","journal-title":"Eur Heart J"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.jacc.2021.01.033","article-title":"Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload","volume":"77","author":"Packer","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure","volume":"77","author":"Ferreira","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B107","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B108","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B109","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"26","author":"McDonagh","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","article-title":"Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes","volume":"146","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: eMPEROR-preserved trial","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"B113","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.121.057812","article-title":"Empagliflozin, health Status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-preserved trial","volume":"145","author":"Butler","year":"2022","journal-title":"Circulation"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2022.04.040","article-title":"Empagliflozin improves outcomes in patients with heart failure and preserved ejection fraction irrespective of age","volume":"80","author":"B\u00f6hm","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1016\/j.jchf.2024.08.020","article-title":"Uric acid and SGLT2 inhibition with empagliflozin in heart failure with preserved ejection fraction","volume":"12","author":"Doehner","year":"2024","journal-title":"JACC Heart Fail"},{"key":"B116","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jchf.2022.05.004","article-title":"Prognostic implications of N-terminal pro\u2013B-type natriuretic peptide and high-sensitivity cardiac troponin T in EMPEROR-preserved","volume":"10","author":"Januzzi","year":"2022","journal-title":"JACC Heart Fail"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/ejhf.2677","article-title":"Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-preserved trial","volume":"24","author":"B\u00f6hm","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B118","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/eurheartj\/ehac693","article-title":"Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-preserved trial","volume":"44","author":"B\u00f6hm","year":"2023","journal-title":"Eur Heart J"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/eurheartj\/ehae864","article-title":"Anaemia, erythrocytosis, and empagliflozin in heart failure with preserved ejection fraction: the EMPEROR-preserved trial","volume":"46","author":"Ferreira","year":"2025","journal-title":"Eur Heart J"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamacardio.2023.0711","article-title":"Effect of dapagliflozin on total heart failure events in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER trial","volume":"8","author":"Jhund","year":"2023","journal-title":"JAMA Cardiol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrcardio.2014.28","article-title":"The inflammatory response in myocardial injury, repair, and remodelling","volume":"11","author":"Frangogiannis","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in acute myocardial infarction: the EMMY trial","volume":"43","author":"Von Lewinski","year":"2022","journal-title":"Eur Heart J"},{"key":"B124","doi-asserted-by":"publisher","first-page":"EVIDoa2300286","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evidence"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"key":"B126","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12933-017-0604-9","article-title":"Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes","volume":"16","author":"Karam","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"B128","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12933-021-01243-4","article-title":"SGLT-2 inhibitors and atrial fibrillation in the food and drug administration adverse event reporting system","volume":"20","author":"Bonora","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12933-024-02137-x","article-title":"Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of > 80,000 patients (the SGLT2i\u2014arrhythmias and sudden cardiac death)","volume":"23","author":"Liao","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes Mellitus: insights from the DECLARE-TIMI 58 trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"B131","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jacep.2023.06.008","article-title":"Impact of SGLT2 inhibitors on AF recurrence after catheter ablation in patients with type 2 diabetes","volume":"9","author":"Abu-Qaoud","year":"2023","journal-title":"JACC Clin Electrophysiol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"132954","DOI":"10.1016\/j.ijcard.2024.132954","article-title":"Impact of sodium-glucose cotransporter 2 inhibitors on catheter ablation for atrial fibrillation in heart failure patients without type-2 diabetes","volume":"422","author":"Harada","year":"2025","journal-title":"Int J Cardiol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1161\/CIRCULATIONAHA.125.077447","article-title":"Dapagliflozin to reduce early recurrence after catheter ablation for atrial fibrillation: the DARE-AF randomized clinical trial","volume":"153","author":"Jiang","year":"2026","journal-title":"Circulation"},{"key":"B134","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.japh.2023.10.010","article-title":"Prevalence of sodium-glucose transporter 2 inhibitor-associated diabetic ketoacidosis in real-world data: a systematic review and meta-analysis","volume":"64","author":"Al-Hindi","year":"2024","journal-title":"J Am Pharm Assoc (2003)"},{"key":"B135","doi-asserted-by":"publisher","first-page":"973129","DOI":"10.3389\/fcvm.2022.973129","article-title":"Risk of hypovolemia associated with sodium\u2013glucose cotransporter-2 inhibitors treatment: a meta-analysis of randomized controlled trials","volume":"9","author":"Rong","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.jacc.2024.01.040","article-title":"Genitourinary tract infections in patients taking SGLT2 inhibitors","volume":"83","author":"Kittipibul","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12933-021-01276-9","article-title":"SGLT2 Inhibitors and lower limb complications: an updated meta-analysis","volume":"20","author":"Lin","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"7057","DOI":"10.3390\/ijms25137057","article-title":"The renoprotective mechanisms of sodium-glucose cotransporter-2 inhibitors (SGLT2i)\u2014a narrative review","volume":"25","author":"Iordan","year":"2024","journal-title":"IJMS"},{"key":"B139","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bja.2019.03.028","article-title":"Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review","volume":"123","author":"Thiruvenkatarajan","year":"2019","journal-title":"Br J Anaesth"},{"key":"B140","doi-asserted-by":"publisher","first-page":"S339","DOI":"10.2337\/dc26-S016","article-title":"16. Diabetes care in the hospital: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"B141","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1007\/s11695-025-08002-4","article-title":"Impact of SGLT2 inhibitors use on risk of postoperative acute kidney injury following metabolic and bariatric surgery: a retrospective study","volume":"35","author":"Chen","year":"2025","journal-title":"Obes Surg"},{"key":"B142","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamasurg.2025.0940","article-title":"Postoperative outcomes among sodium-glucose cotransporter 2 inhibitor users","volume":"160","author":"Tallarico","year":"2025","journal-title":"JAMA Surg"},{"key":"B143","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jamasurg.2024.7082","article-title":"Preoperative SGLT2 inhibitor use and postoperative diabetic ketoacidosis","volume":"160","author":"Dixit","year":"2025","journal-title":"JAMA Surg"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1776906\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:34:33Z","timestamp":1780979673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1776906\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":143,"alternative-id":["10.3389\/fcvm.2026.1776906"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1776906","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"article-number":"1776906"}}